A pivotal role for glutamate in the pathogenesis of schizophrenia, and its cognitive dysfunction

Pharmacology Biochemistry and Behavior

Volumn 56, Issue 4, 1997, Pages 797-802

  Hirsch, Steven R ^a   Das, Indrajit ^a   Garey, Laurence J ^a   De Belleroche, Jacqueline ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

cognitive deterioration; glutamate hypothesis; NMDA hypofunction; schizophrenia

Indexed keywords

CLOZAPINE; CYCLOSERINE; DIZOCILPINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; KETAMINE; MESSENGER RNA; MILACEMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; POLYAMINE; RECEPTOR SUBTYPE; SPERMIDINE; SPERMINE;

ANIMAL MODEL; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DENDRITIC SPINE; DOPAMINERGIC SYSTEM; ELECTROPHYSIOLOGY; FRONTAL CORTEX; HUMAN; HYPOTHESIS; MEMORY; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; PUBERTY; PYRAMIDAL NERVE CELL; SCHIZOPHRENIA; TEMPORAL CORTEX;

ANIMALIA; MAMMALIA;

EID: 0030966724     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00428-5     Document Type: Article

References (51)

1. Akbarian S., Kim J. J., Potkin S. G., Hertrick W. P., Bunney W. E., Jones E. G. Maldistributing of interstitial neurons in prefrontal white matter of the brain of schizophrenic patients. Arch. Gen. Psychiatry. 53:1996;425-436.
2. Allen M., Young S. Phencyclidine induced psychosis. Am. J. Psychiatry. 135(9):1978;1081-1084.
3. Bliss T. V. P., Collingridge G. L. A synaptic model of memory. Long-term potentiation Nature. 361:1993;31-39.
4. Carlsson A. The dopamine theory revisited. Hirsch S. R., Weinberger D. R. Schizophrenia. 1995;379-400 Blackwell Science, Oxford, UK.
5. Costall B., Naylor R. Animal neuropharmacology and its prediction of clinical response. Hirsch S. R., Weinberger D. R. Schizophrenia. 1995;401-424 Blackwell Science, Oxford, UK.
6. Crow T. J., MacMillan J. F., Johnson A. L., Johnstone E. C. The Northwick Park study of first-episode schizophrenia II. A randomised controlled trial of prophylactic neuroleptic treatment. Br. J. Psychiatry. 148:1986;120-127.
7. Das I., Adams C., Essali M. A., de Belleroche J., Hirsch S. R. Blood polyamines in schizophrenia. A study of clozapine in drug resistant schizophrenic patients Schizophr. Res. 6:1992;175.
8. Das I., Essali M. A., de Belleroche J., Hirsch S. R. Neuroleptics may exert their effect by modulating NMDA subtype of glutamate receptor in schizophrenia. Biol. Psychiatry. 29:1991;280S.
9. Deakin J. F. W., Slater P., Simpson M. D. C., Gilchrist A. C., Skan W. J., Royston M. C., Reynolds G. P., Cross A. J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52:1989;1781-1786.
10. Deakin J. F. W., Slater P., Simpson M. D. C., Royston M. C. Disturbed brain glutamate and GABA mechanisms in schizophrenia. Schizophr. Res. 3:1990;33.
11. Durnin A. T., Mortimer A., Barnes T. R. E., Hirsch S., de Belleroche J. Is the expression of cholecystokinin mRNA in schizophrenia region specific? Schizophr. Res. 18:1996;176.
12. Eastwood S. L., McDonald B., Burnet W. J., Beckwith J. P., Kerwin R. W., Harrison P. J. Decreased expression in mRNA's encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Mol. Brain Res. 29:1995;211-223.
13. Eastwood S. L., Porter R. H. P., Burnet P. W. J., Kerwin R. W., Harrison P. J. Non glutamate receptor expression in schizophrenia. Schizophr. Res. 18(23):1996;174.
14. Falkai P., Bogerts B. The neuropathology of schizophrenia. Hirsch S. R., Weinberger D. R. Schizophrenia. 1995;275-292 Blackwell Science, Oxford, UK.
15. Fonnum F., Myhrer T., Paulsen R. E., Wangen K., Oksengard A. R. Role of glutamate and glutamate receptors in memory function and Alzheimer's disease. Ann. N.Y. Acad. Sci. 757:1995;475-486.
16. Frith C. D., Friston K. J., Herold S., Silbersweg D., Fletcher P., Cahill C., Dolan R. J., Frackowiak R. S. J., Liddle P. F. Regional brain activity in chronic schizophrenic patients during the performance of a verbal fluency task. Br. J. Psychiatry. 167:1995;343-349.
17. Garey L. J., Ong W. Y., Patel T. S., Kanani M., Davis A., Hornstein C., Bauer M. Reduction in dendritic spine number on cortical pyramidal neurons in schizophrenia. Soc. Neurosci. Abstr. 21:1995;237.
18. Goff D., Tsai G., Manoach D. S., Coyle J. T. Dose-findings trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry. 152:1995;1215.
19. Goldberg T. E., Gold J. M. Neurocognitive deficits in schizophrenia. Hirsch S. R., Weinberger D. R. Schizophrenia. 1995;146-162 Blackwell Science, Oxford, UK.
20. Halpain S., Girault S. A., Greengard P. Activation of NMDA receptors induces dephosphorylation of DAPPP-32 in striatal slices. Nature. 343:1990;369-371.
21. Harrison P. J. Non NMDA glutamate receptor expression in schizophrenia. Schizophr. Res. 18:1996;174.
22. Hirsch S. R., Barnes T. R. E. The clinical treatment of schizophrenia with antipsychotic medication. Hirsch S. R., Weinberger D. R. Schizophrenia. 1995;440-445 Blackwell Science, Oxford, UK.
23. Hirsch S. R., Richardson-Andrews R., Costall B., Kelly M. E., de Belleroche J., Naylor R. J. The effects of some polyamines on putative behavioural indices of mesolimbic versus striatal dopaminergic function. Psychopharmacology. 93:1987;101-104.
24. Humphries C. R., Mortimer A., Barnes T. R. E., Hirsch S. R., de Belleroche J. Expression of the N-methyl-D-aspartate receptor subunit NR-1 messenger RNA in schizophrenia. Schizophr. Res. 18:1996;174-175.
25. Humphries C. R., Mortimer A., Hirsch S. R., de Belleroche J. NMDA receptor RNA correlation with antemortem cognitive impairment in schizophrenia. NeuroReport. 7:1996;2051-2055.
26. Javitt D. C., Doneshka P., Grochowski S., Ritter W. Impaired mismatch negativity generation reflects widespread dysfunction of working memory in schizophrenia. Arch. Gen. Psychiatry. 52:1995;550-558.
27. Javitt D. C., Schroeder C. E., Steinschneider M., Arezzo J. C., Ritter W., Vaughan H. G. Jr. Cognitive event-related potentials in human and non-human primates. Implications for the PCP/NMDA model of schizophrenia In. Karmos, G.; Molnar, M.; Csepe, V.; Czigler, Z.; Desmedt, J. E., eds. Perspectives of event-related potentials research (EEG suppl. 44). Amsterdam:1994;161-175. Elsevier Science Publishers;
28. Javitt D. C., Zukin S. R. Role of excitatory amino acids in neuropsychiatric illness. J. Neuropsychiatry Clin. Neurosci. 2:1990;44-52.
29. Javitt D. C., Zukin S. R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308.
30. Javitt D. C., Zylberman I., Zukin S. R., Heresco-Levy U., Lindenmayer J.-P. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry. 151(8):1994;1234-1236.
31. Kerwin R. W., Patel S., Meldrum B. S., Czudek C., Reynolds G. P. Asymmetrical loss of glutamate receptor subtype in left hippocampus in schizophrenia. Lancet. 1:1988;583-584.
32. Kerwin R. W., Patel S., Meldrum B. S. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain postmortem. Neuroscience. 39:1990;25-32.
33. Kim J. S., Kornhuber H. H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenia patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
34. Loebel A. D., Lieberman J. A., Alvir J. M. J., Mayerhoff D. I., Geisler S. H. Duration of psychosis and outcome in first-episode schizophrenia. Am. J. Psychiatry. 149:1993;1183-1188.
35. Lund J. S., Lund R. D., Hendrickson A. E., Bunt A. H., Fuchs A. F. The origin of efferent pathways from primary visual cortex, area 17, of the macaque monkey as shown by retrograde transport of horseradish peroxidase. J. Comp. Neurol. 164:1975;287-303.
36. McEntee W. J., Crook T. H. Glutamate. Its role in learning, memory and the aging brain Psychopharmacology. 111:1993;391-401.
37. Morris R. G. M., Anderson E., Lynch G. S., Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature. 319:1986;774-776.
38. 3H]kainic acid-binding in the pre-frontal cortex in schizophrenia. Neurosci. Lett. 40:1983;245-250.
39. Olney J., Farber N. B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
40. Owen F., Simpson M. D. C. The neurochemistry of schizophrenia. Hirsch S. R., Weinberger D. R. Schizophrenia. 1995;358-378 Blackwell Science, Oxford, UK.
41. 3H)dopamine release from rat striatum. An in vitro model for glutamate action J. Neurochem. 32:1979;1539-1545.
42. Schwarcz R., Creese I., Coyle J. T., Snyder S. H. Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature. 271:1978;766-778.
43. Selemon L. D., Rajkowska G., Goldman-Rakic P. S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry. 52:1995;805-818.
44. 3H)-TCP binding sites in Alzheimer's disease brains. Brain Res. 462:1988;76-82.
45. Simpson M. D. C., Slater P., Royston M. C., Deakin J. F. W. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication Schizophr. Res. 6:1992;41-48.
46. Smiley J. F., Williams S. M., Szigeti K., Goldman-Rakic P. S. Light and electron microscopic characterization of dopamine-immunoreactive axon in human cerebral cortex. J. Comp. Neurol. 321:1992;325-335.
47. Steinnmeis R. The behavioural and neurochemical effect of phenylcyclidine in humans and animals; some implications for modeling psychosis. Behav. Brain Res. 74:1996;45-55.
48. Toru M., Watanabe S., Shibuya H. Neurotransmitters, receptors and neuropeptides in postmortem brains of chronic schizophrenic patients. Psychiatr. Scand. 78:1988;121-137.
49. Utas J., Cotman C. W. Excitatory amino acid receptors in schizophrenia. Schizophr. Bull. 19:1993;105-117.
50. von Bussmann K. A., Rodway A., Gentleman S. M., Garey L. J., Hirsch S. R. Decreased glutamatergic binding sites in the left orbito-frontal cortex of chronic schizophrenics. Schizophr. Res. 18:1996;175.
51. Waziri R. Glycine therapy of schizophrenia. Biol. Psychiatry. 23:1988;210-211.